Nuvectis Pharma (NVCT) stock: insider trades, news & valuation
Strong buyingShare price and insider trades
Nuvectis Pharma insider trading at a glance (Oct 9, 2026): in the past 12 months, 4 insiders bought $2.3M and 0 sold $0 of NVCT stock on the open market, including a cluster buy that began Oct 23, 2025.
Get emailed when insiders cluster-buy stocks like NVCT
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
NVCT insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | $1.2M | 2 | — | 0 |
| Q1 2026 | — | 0 | — | 0 |
| Q4 2025 | $1.1M | 6 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 4 Nuvectis Pharma, Inc. insiders reported open-market purchases totaling $2.3M, while 0 insiders reported sales totaling $0. The most recent cluster buy began on Oct 23, 2025, when 4 insiders bought a combined $1.1M. Among insiders with enough purchase history to measure, Ron Bentsur (CEO, Chair) has the highest Insider Score at 84.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jul 1SEC | Marlio Charles Mosseri10% Owner | Buy | 50,0003,186,576 held (+2%) | $18.32 | $916K | +15.3% | 73 |
| Jul 1SEC | Ron BentsurCEO, Chair | Buy | 12,5003,688,424 held (+0%) | $20.00 | $250K | +5.6% | 84 |
| Nov 6SEC | Juan SanchezDirector | Buy | 13,00078,150 held (+20%) | $5.79 | $75K | +264.8% | — |
| Nov 6SEC | Matthew L. KaplanDirector | Buy | 11,000124,760 held (+10%) | $5.84 | $64K | +261.6% | — |
| Nov 6SEC | Ron BentsurCEO, Chair | Buy | 5,0003,525,924 held (+0%) | $5.72 | $29K | +269.2% | 84 |
| Oct 29SEC | Marlio Charles Mosseri10% Owner | Buy | 72,8363,136,576 held (+2%) | $6.28 | $457K | +236.3% | 73 |
| Oct 29SEC | Marlio Charles Mosseri10% Owner | Buy | 46,9003,028,706 held (+2%) | $6.06 | $284K | +248.5% | 73 |
| Oct 29SEC | Marlio Charles Mosseri10% Owner | Buy | 35,0343,063,740 held (+1%) | $6.15 | $215K | +243.4% | 73 |
Insiders at Nuvectis Pharma, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Marlio Charles Mosseri10% Owner | $1.9M | — | Jul 1, 2026 | 73 |
| Ron BentsurCEO, Chair | $279K | — | Jul 1, 2026 | 84 |
| Juan SanchezDirector | $75K | — | Nov 6, 2025 | — |
| Matthew L. KaplanDirector | $64K | — | Nov 6, 2025 | — |
NVCT stock: common questions
Are Nuvectis Pharma, Inc. insiders buying NVCT stock?
In the past 12 months, 4 insiders reported open-market purchases of NVCT worth $2.3M. The latest was 10% Owner Marlio Charles Mosseri bought $916K of NVCT at $18.32 — largest purchase by this insider in our records.
Are Nuvectis Pharma, Inc. insiders selling NVCT stock?
0 insiders reported sales worth $0 over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is NVCT's 52-week range?
Over the past year NVCT has traded between $5.65 and $28.53. It last closed at $21.12 on Oct 9, 2026.